



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 12th August, 2025

BSE Limited

Dept. of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
BSE Scrip Code - 541304

National Stock Exchange of India Limited

Dept. of Corporate Compliances,
Exchange Plaza, C-1 Block-G,
Bandra Kurla Complex,
Bandra (E) Mumbai- 400 051
NSE Symbol: INDOUS

**Sub: Outcome of Board Meeting held on August 12, 2025, pursuant to Regulation 30 of the SEBI
(Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Tuesday, 12th August, 2025 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter ended 30th June, 2025 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 14.00 P.M. and concluded at 14:30 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI

Digitally signed by DIMPY
DIVYANGBHAI JOSHI
Date: 2025.08.12 14:31:25
+05'30'

Ms. Dimpy Joshi

Company Secretary & Compliance officer






INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited

CIN: LO1122GJ2004PLC043550

Regd Office: 309, Shanti Mall, Satadhar Char Rasta Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, India, 380061

PARTICULARS	Quarter Ended			Year ended
	6/30/2025 (Unaudited)	3/31/2025 (Audited)	6/30/2024 (Unaudited)	3/31/2025 (Audited)
I Income				
Revenue from operations	3,076.96	3,338.46	2,471.77	10,383.84
Other income	0.15	11.95	2.80	18.20
Total income from operations	3,077.11	3,350.41	2,474.57	10,402.04
II Expenses				
Purchases	715.14	2,008.25	13.39	2,054.93
Production Expenses	883.95	3,082.93	1,262.35	7,096.30
Change in Inventories	613.24	(2,649.95)	529.93	(1,885.48)
Employee benefit expenses	32.06	33.63	28.82	109.35
Finance costs	45.10	25.87	32.99	148.82
Depreciation and amortization expenses	20.04	56.41	20.01	109.78
Other expenses	285.59	405.36	268.25	1,115.28
Total expenses	2,595.12	2,962.50	2,155.75	8,748.98
III Profit/(Loss) before exceptional items and tax	481.99	387.91	318.82	1,653.06
IV Exceptional items- Prior Period Items				
V Profit/(Loss) before tax	481.99	387.91	318.82	1,653.06
VI Tax expenses				
a) Current tax	6.95	31.67	0.78	31.67
b) Income tax prior year		-1.68		-1.68
c) Deferred tax	4.80	-10.56	1.18	(3.68)
Total tax expenses	11.75	19.44	1.96	26.32
VII Net Profit/(Loss) for the period/year	470.24	368.47	316.86	1,626.74
VIII Other comprehensive income (net of tax)				
Items that will not be reclassified to profit or loss:				
i) Remeasurement of post employment benefit obligations	-0.29	-3.93	-	-0.52
ii) Income-tax relating to items that will not be reclassified to profit or loss	0.07	-	-	-
Total other comprehensive income	-0.21	-3.93	-	-0.52
IX Total comprehensive income for the period/year (VII+VIII)	470.45	372.40	316.86	1,627.26
X Paid-up equity share capital (face value of Rs.10 per share)	2,005.20	2,005.20	2,005.20	2,005.20
XI Other equity (excluding revaluation reserve)				5,846.65
XII EPS in Rs. (Face Value of Rs.10/- each)*				
-Basic	2.35	1.86	1.58	8.12
-Diluted	2.35	1.86	1.58	8.12
*not annualised				

Notes

- (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th August 2025 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation, Processing & Trading.
- (3) There were no investor complaints pending /received during the period under review.
- (4) The figures have been regrouped/rearranged wherever necessary.



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

GAUTAM NAWAWAT
(Partner)

Place: Ahmedabad
Date: 12th August 2025



For and on behalf of Board of Directors
For, INDO US BIO TECH LIMITED

Jagdish D. Audani
Managing Director
DIN: 01745951

UDIN-25082742BMJJNK1313

Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.

LIMITED REVIEW REPORT

To,
The Board of Directors,
Indo US Bio-Tech Limited,
Ahmedabad

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Indo US Bio-Tech Limited** (CIN: L01122GJ2004PLC043550) (the company) for the quarter ended 30th June 2025 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (Listing Regulations).
2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued there under and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules made thereunder and other accounting principles generally accepted in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates

Chartered Accountants


FRN: 103117W


Gautam Mandawat

Partner,

M No: 032742

UDIN: **25032742BMJJNK1313**



Place: Chhatrapati Sambhajinagar

Date: 12th August 2025